Replies to post #246800 on Avid Bioservices Inc (CDMO)

[Couch]

Yeah NOTHING absolutely NOTHING going on right around here. Next

Equally exciting is the Phase II/III metastatic HER2- breast cancer study that we are looking forward to starting by year-end. I say exciting because the new trial design has a solid clinical data basis, and our previously completed Phase I & II trials in a patient population in these new treatment options. While we don’t have the same benefit as we do for the lung cancer program of rolling right from one study into another, the team has been working diligently to get the study started by the year-end, giving us additional enrollment months, which again can put us on track for some meaningful clinical data from the study by early 2017.

The company is also working diligently on a number of other studies, including our other collaboration with AstraZeneca, evaluating a combination of bavi with chemotherapy and adding in again their durvalumab antibody in multiple solid tumor indications. So, conceptually, “get an immune response going with chemotherapy & Bavi, and then keep it going with durvalumab”.

[stoneroad]

So have the snarky "Goats" sold their positions? Or is Bavi going to be on the market in March? The truth is more likely somewhere in between.

[pphmtoolong]

Guaranteed success? No. Reasons to expect success? Yes. The nice thing is we will get a meaningful answer in a few months. Not a lot of months, not a lot of years.

After a very long process, Bavi has a chance to prove itself among the immunotherapy elite.

GLTA, Especially Bavi-arm Sunrise Patients,

Paul